American Heart Journal
Volume 158, Issue 5 , Pages 742-747 , November 2009

Reporting and representation of race/ethnicity in published randomized trials

  • Jeffrey S. Berger, MD, MS

      Affiliations

    • New York University School of Medicine, New York, NY
    • Duke Clinical Research Institute, Durham, NC
    • Corresponding Author InformationReprint requests: Jeffrey S. Berger, MD, MS, The Leon H. Charney Division of Cardiology, New York University School of Medicine, 530 First Avenue, Skirball 9R, New York, NY 10016.
    • ,
  • Chiara Melloni, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Tracy Y. Wang, MD, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Rowena J. Dolor, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Camille G. Frazier, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Zainab Samad, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Daniel B. Mark, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • L. Kristin Newby, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC

Received 8 June 2009 ,Accepted 21 August 2009.

References 

  1. Ferdinand KC. Coronary artery disease in minority racial and ethnic groups in the United States. Am J Cardiol. 2006;97:12A–19A
  2. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001;135:352–366
  3. Sonel AF, Good CB, Mulgund J, et al. Racial variations in treatment and outcomes of black and white patients with high-risk non–ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation. 2005;111:1225–1232
  4. Fincher C, Williams JE, MacLean V, et al. Racial disparities in coronary heart disease: a sociological view of the medical literature on physician bias. Ethn Dis. 2004;14:360–371
  5. Nasir K, Shaw LJ, Liu ST, et al. Ethnic differences in the prognostic value of coronary artery calcification for all-cause mortality. J Am Coll Cardiol. 2007;50:953–960
  6. Peterson ED, Wright SM, Daley J, et al. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. JAMA. 1994;271:1175–1180
  7. US Food and Drug Administration . Guideline for the Study of Drugs Likely to Be Used in the Elderly. Rockville (Md): Food and Drug Administration/Center for Drug Evaluation and Research; 1989;
  8. National Institutes of Health guidelines on the inclusion of women and minorities as subjects in clinical research, 59 Federal Register. 11146 (1994). Available at: http//grants.nih.gov/grants/guide/notice–files/not94–100.html. Accessed September 15, 2009.
  9. U.S. Congress Public Law 103-43: National Institutes of Health Revitalization Act of 1993; 1993 [Washington, DC]. Available at: http://grants.nih.gov/grants/guides/rfa–files/RFA–HS–95–004.html. Accessed September 15, 2009.
  10. Buring JE. Women in clinical trials—a portfolio for success. N Engl J Med. 2000;343:505–506
  11. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475–480
  12. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708–713
  13. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–2067
  14. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–2726
  15. Djomand G, Katzman J, di Tommaso D, et al. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep. 2005;120:543–548
  16. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481–1501
  17. Kaplan JB, Bennett T. Use of race and ethnicity in biomedical publication. JAMA. 2003;289:2709–2716
  18. Protocol Registration System and U.S. Public Law 110-85. Available at: http://prsinfo.clinicaltrials.gov/fdaaa.htmlAccessed August 20, 2009
  19. Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest. 2009;136:295–303
  20. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417–423
  21. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332:1177–1181
  22. Berger JS, Bairey-Merz CN, Redberg RF, et al. Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007. Am Heart J 2008;156:816-825, 825 e811.

PII: S0002-8703(09)00658-9

doi: 10.1016/j.ahj.2009.08.018

American Heart Journal
Volume 158, Issue 5 , Pages 742-747 , November 2009

Article Tools

* Image Usage & Resolution